Ascendis Pharma (ASND) Misses Q3 EPS by 18c, provides outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ascendis Pharma (ASND) PT Lowered to $200 at Citi
November 15, 2024 7:10 AM ESTCiti analyst David Lebowitz lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $200.00 (from $207.00) while maintaining a Buy rating.
The analyst comments "Ascendis reported 3Q24 financial results, missing Street estimates on topline revenue and GAAP EPS, as the Skytrofa challenges that emerged... More
Ascendis Pharma (ASND) PT Lowered to $180 at Oppenheimer
November 15, 2024 6:21 AM ESTOppenheimer analyst Leland Gershell lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $180.00 (from $190.00) while maintaining a Outperform rating.
The analyst comments "ASND reported 3Q net loss of 99.2M vs. our expected 110.2M as management continues to effectively manage expenses. Skytrofa revenue of... More
